已发表论文

通过递送 3-十八烷基氨基甲酰丙烯酸 - 顺铂 (Cisplatin) 脂质体来逆转人肺癌细胞中的多药耐药性

 

Authors Song J, Ren W, Xu T, Zhang Y, Guo H, Zhu S, Yang L

Received 17 October 2016

Accepted for publication 16 November 2016

Published 17 February 2017 Volume 2017:11 Pages 441—449

DOI https://doi.org/10.2147/DDDT.S124912

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 4

Editor who approved publication: Dr Anastasios Lymperopoulos

Abstract: Liposome-based drug delivery system would be an innovative and promising candidate to circumvent multidrug resistance (MDR) of cisplatin (CDDP). However, the reversal efficacy of liposomal CDDP was severely impaired by weak cellular uptake and insufficient intracellular drug release. In this study, 3-octadecylcarbamoylacrylic acid–CDDP nanocomplex (OMI–CDDP–N)-based liposomes (OCP-L) with high cellular uptake and sufficient intracellular drug release were designed to circumvent MDR of lung cancer. OMI–CDDP–N was synthesized through a pH-sensitive monocarboxylato and an OPt coordinate bond, which is more efficient than CDDP. Also, OCP-L incorporated with OMI–CDDP–N could induce effective cellular uptake, enhanced nuclear distribution, and optimal cellular uptake kinetics. In particular, OCP-L presented superior effects on enhancing cell apoptosis and in vitro cytotoxicity in CDDP-resistant human lung cancer (A549/CDDP) cells. The mechanisms of MDR reversal in A549/CDDP cells by OCP-L could attribute to organic cation transporter 2 restoration, ATPase copper-transporting beta polypeptide suppression, hypoxia-inducible factor 1 α-subunit depletion, and phosphatidylinositol 3-kinase/Akt pathway inhibition. These results demonstrated that OCP-L may provide an effective delivery of CDDP to resistant cells to circumvent MDR and enhance the therapeutic index of the chemotherapy.
Keywords: 3-octadecylcarbamoylacrylic acid-cisplatin nanocomplexes, liposomes, cellular uptake, multidrug resistance, therapeutic index